Taysha Gene Therapies (NASDAQ:TSHA) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Taysha Gene Therapies (NASDAQ:TSHA – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday.

Several other analysts also recently weighed in on the stock. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research report on Wednesday, November 5th. Robert W. Baird raised their price target on shares of Taysha Gene Therapies from $7.00 to $12.00 and gave the company an “outperform” rating in a research note on Thursday, October 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a report on Friday, November 14th. UBS Group set a $11.00 price objective on Taysha Gene Therapies in a report on Thursday, December 4th. Finally, Citizens Jmp lifted their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “market outperform” rating in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.42.

Read Our Latest Stock Analysis on Taysha Gene Therapies

Taysha Gene Therapies Stock Performance

TSHA stock opened at $5.76 on Friday. The stock’s 50 day simple moving average is $4.72 and its 200 day simple moving average is $3.50. Taysha Gene Therapies has a 12-month low of $1.05 and a 12-month high of $5.95. The firm has a market cap of $1.58 billion, a P/E ratio of -17.45 and a beta of 1.06. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. As a group, equities research analysts predict that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Buying and Selling at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 260,047 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the completion of the sale, the insider directly owned 1,006,439 shares in the company, valued at approximately $4,539,039.89. The trade was a 20.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.78% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

Institutional investors and hedge funds have recently bought and sold shares of the business. Marex Group plc purchased a new position in Taysha Gene Therapies in the 2nd quarter worth approximately $29,000. E Fund Management Co. Ltd. purchased a new stake in Taysha Gene Therapies in the 2nd quarter valued at $31,000. ST Germain D J Co. Inc. grew its holdings in Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after buying an additional 4,333 shares in the last quarter. May Hill Capital LLC acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth $37,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in shares of Taysha Gene Therapies during the 3rd quarter worth $40,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

(Get Free Report)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

Read More